本帖最后由 老马 于 2012-1-13 21:20 编辑
E" z. R9 K/ Z4 k+ {
2 d( o, x; g* q6 n+ l爱必妥和阿瓦斯丁的比较$ H% x2 w0 l7 E# _- }
+ V- Y; x* B) H
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/' W; }4 r% t9 K: T V
1 y9 G+ `3 k& Y
+ G7 {7 ^. l4 H, W: f! Rhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
/ u6 n+ Q+ O6 J$ W+ M6 n==================================================& c+ R. w' f' d5 B' h
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)5 b* H/ p2 D9 g9 h6 `6 m/ @
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
& d8 o% S. ?( W0 L. CResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
- j3 ?" o6 j+ t) w
|